Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Completed · Phase 2

Conditions studied: Melanoma, Malignant Metastatic Melanoma

In brief

The primary objectives of this study are: * To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma. * To determine the safety of MEDI-522 ± DTIC in this patient population.

Key facts

Study ID
NCT00066196
Run by
MedImmune LLC
People needed
110
Starts
2003-08-01
Expected to finish
2007-06-01
Last updated by the study team
2008-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.